Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation medicines for the treatment of cancer and autoimmune diseases. Headquartered in San Francisco, California, the company utilizes its proprietary DELigase platform, which combines DNA-encoded libraries with E3 ligase expertise, to create small molecule therapies that modulate cellular protein levels. Its wholly owned clinical pipeline includes degraders of Bruton's tyrosine kinase (BTK) for B-cell malignancies and inhibitors of the CBL-B ligase to enhance immune cell activation. In addition to its internal programs, Nurix has established strategic collaborations with major pharmaceutical companies, including Sanofi, Gilead Sciences, and Pfizer, to advance novel degrader therapies and degrader-antibody conjugates.
